Zenas BioPharma, Inc. Common Stock - Asset Resilience Ratio
Zenas BioPharma, Inc. Common Stock (ZBIO) has an Asset Resilience Ratio of 63.64% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Zenas BioPharma, Inc. Common Stock to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how Zenas BioPharma, Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Zenas BioPharma, Inc. Common Stock balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Zenas BioPharma, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ZBIO strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $446.55 Million | 63.64% |
| Total Liquid Assets | $446.55 Million | 63.64% |
Asset Resilience Insights
- Very High Liquidity: Zenas BioPharma, Inc. Common Stock maintains exceptional liquid asset reserves at 63.64% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Zenas BioPharma, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Zenas BioPharma, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Celldex Therapeutics Inc
NASDAQ:CLDX |
Biotechnology | 81.32% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Savara Inc
NASDAQ:SVRA |
Biotechnology | 68.30% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
Annual Asset Resilience Ratio for Zenas BioPharma, Inc. Common Stock (2023–2025)
The table below shows the annual Asset Resilience Ratio data for Zenas BioPharma, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 60.62% | $232.55 Million | $383.64 Million | +52.23pp |
| 2024-12-31 | 8.39% | $31.02 Million | $369.97 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $68.18 Million | -- |
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, an… Read more